SC 13G: Mineralys Therapeutics, Inc.
Ticker: MLYS · Form: SC 13G · Filed: Feb 13, 2024 · CIK: 1933414
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Mineralys Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 8.2 · Accepted 2024-02-13 16:09:21
Key Financial Figures
- $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
Filing Documents
- tm245871d5_sc13g.htm (SC 13G) — 38KB
- 0001104659-24-019880.txt ( ) — 40KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. By: /s/ Jean-Marc LeSieur Name: Jean-Marc LeSieur Title: Managing Director SIGNATURE PAGE TO SCHEDULE 13G (MINERALYS THERAPEUTICS, INC.)